Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1515)	3/8/1999 2:05:00 PM
From: Dan Spillane	Respond to of 2539

...agreed; it's also probably safe to say no merger/buyout is priced into the stock at this point. You said: Coyote, I guess some are selling because there's no "merger" announcement today. Low volume so far.

To: Anthony Wong who wrote (1515)	3/8/1999 3:06:00 PM
From: Exacctnt	Read Replies (1) \| Respond to of 2539

Anthony, CNBC had a Dow Jones reporter say that Monsanto was down today because of poor results on an anti-clotting drug was released over the weekend. I don't know if this is another rehash job, or not. I don't see any news reports on this. Regards, Bob

To: Anthony Wong who wrote (1515)	3/8/1999 3:14:00 PM
From: Exacctnt	Read Replies (1) \| Respond to of 2539

Anthony, Found the Dow Jones article. As I suspected, it's on a drug previously disclosed with poor results. Study: Searle Heart Drug Showed No Significant Benefit (This story was first published Sunday, March 7.) By Raymond Hennessey NEW ORLEANS (Dow Jones)--Patients given Searle & Co.'s anti-clotting drug Xemilofiban after angioplasty or stenting of blood vessels showed virtually no longer term improvement over patients not given the drug. Searle's parent, Monsanto Corp. (MTC) pulled the plug on development of Xemilofiban and a close relative, orbofiban, a few months ago. In results presented here Sunday at the American College of Cardiology Scientific Sessions, Dr. William O'Neill of William Beaumont Hospital in Royal Oak,, Mich., said patients given either a 10mg or 20mg dose after angioplasty had a reduction in deaths or heart attacks in the first two days after their procedure, but "unfortunately, this early benefit achieved by the drug was not maintained." In fact, as time went on, patients not given the drug had the same health effects as those treated with either dose of Xemilofiban, O'Neill said. Any benefits from Xemilofiban "dissipated after the first 48 hours," he said. In only one set of patients - those with diabetes - did Xemilofiban show any benefits, though O'Neill said further study on those patients is necessary. The study, known as the Excite trial, involved 467 sites in 29 countries and produced about 254,000 pages of data. "This was truly a global, massive effort," O'Neill said. There was, however, one odd difference between Excite and the other major interventional cardiology trials conducted, such as the Epistent and Epilog trials, O'Neill said: In Excite, there was a dramatic difference in the incidence of death or heart attack among all patients regardless of treatment compared with the earlier trials, he said. Regards, Bob